In this paper we propose the use of a random network model for simulating and understanding the epidemics of influenza A(H1N1). The proposed model is used to simulate the transmission process of influenza A(H1N1) in a community region of Venezuela using distributed computing in order to accomplish many realizations of the underlying random process. These large scale epidemic simulations have recently become an important application of high-performance computing. The network model proposed performs better than the traditional epidemic model based on ordinary differential equations since it adjusts better to the irregularity of the real world data. In addition, the network model allows the consideration of many possibilities regarding the spread of influenza at the population level. The results presented here show how well the SEIR model fits the data for the AH1N1 time series despite the irregularity of the data and returns parameter values that are in good agreement with the medical data regarding AH1N1 influenza virus. This versatile network model approach may be applied to the simulation of the transmission dynamics of several epidemics in human networks. In addition, the simulation can provide useful information for the understanding, prediction and control of the transmission of influenza A(H1N1) epidemics.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.actatropica.2014.12.008DOI Listing

Publication Analysis

Top Keywords

influenza ah1n1
16
network model
16
random network
8
distributed computing
8
data ah1n1
8
model
7
ah1n1
6
network
5
influenza
5
modelling influenza
4

Similar Publications

Effectiveness of influenza vaccination in preventing confirmed influenza cases and hospitalizations in Northern Spain, 2023/24 season: A population-based test-negative case-control study.

Int J Infect Dis

December 2024

Instituto de Salud Pública de Navarra, Pamplona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.

Objective: We estimated the influenza vaccination effectiveness (IVE) in preventing medical consultations and hospitalizations due to influenza during the 2023/24 season.

Methods: Two test-negative case-control studies analyzed patients who consulted primary healthcare or were hospitalized for respiratory symptoms and were tested for influenza by PCR in the 2023/24 season in Navarre, Spain. Influenza vaccination status in the current and previous seasons was compared between confirmed influenza cases and test-negative controls.

View Article and Find Full Text PDF

According to sparse information from various countries, the seasonal influenza virus circulation has drastically decreased during the COVID-19 pandemic. Here, we show the cross-reactivity of anti-SARS-CoV-2 antibodies against influenza viruses. Plasma samples were collected from 311 SARS-CoV-2 infected individuals.

View Article and Find Full Text PDF
Article Synopsis
  • Epidemiological studies show that factors like pre-vaccination immune status, age, gender, and vaccination history affect how people respond to influenza vaccines, but results vary across different studies.* -
  • A new Bayesian model was created to analyze the relationships between these host factors and antibody responses after vaccination, revealing that pre-vaccination antibody levels and vaccination history significantly affect post-vaccine antibody dynamics.* -
  • The findings suggest that individuals who have been vaccinated less frequently and have lower pre-vaccination antibody levels experience longer durations of effective protection (seroprotection) from the vaccine, with notable differences observed in antibody response to different influenza subtypes.*
View Article and Find Full Text PDF

Influenza A (H1N1) virus has been one of the most common threats to humankind since 1918. The viral genome is frequently substituted, leading to new strains and recurrent pandemics. Despite knowing the effects of single amino acid substitutions on individual viral proteins, the effects of collective substitutions on viral infection remain elusive.

View Article and Find Full Text PDF

Background: Coadministration of a respiratory syncytial virus (RSV) vaccine with seasonal influenza or SARS-CoV-2 vaccines could reduce health-care visits and increase vaccination uptake in older adults who are at high risk for severe respiratory disease. The RSV mRNA-1345 vaccine demonstrated efficacy against RSV disease with acceptable safety in the ConquerRSV trial in adults aged 60 years and older. We aimed to evaluate the safety and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine or SARS-CoV-2 mRNA vaccine.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!